全球人乳頭瘤病毒 (HPV) 疫苗市場 - 預測 (2022-2027)

在預測期內，全球人乳頭瘤病毒 (HPV) 疫苗市場規模將以 14.68% 的複合年增長率增長，預計將從 2020 年的 2,030,136,000 美元增長到 2027 年的 5,296,808,000 美元。 推動市場增長的主要因素包括宮頸癌患者數量的增加以及由於政府政策的加強而提高了公眾對 HPV 和宮頸癌的認識。 另一方面，嚴格的疫苗監管許可程序可能會限制市場擴張。

本報告研究全球人乳頭瘤病毒 (HPV) 疫苗市場，按類型、適應症、性別和地區提供市場概況、市場規模和預測、趨勢、驅動因素和限制因素。它提供不同的分析、競爭格局等。

內容

第一章介紹

• 市場概覽
• COVID-19 情景
• 市場定義
• 市場細分

第二章研究方法論

• 調查數據
• 先決條件

第 3 章執行摘要

• 調查要點

第四章市場動態

• 市場驅動因素
• 市場製約因素
• 波特的五力分析
  • 供應商的議價能力
  • 買家的議價能力
  • 新進入者的威脅
  • 替代品的威脅
  • 行業內競爭公司之間的敵對關係
• 行業價值鏈分析

第 5 章人乳頭瘤病毒 (HPV) 疫苗市場類型分析

• 簡介
• 四價 HPV 疫苗
• 二價 HPV 疫苗
• 九價 HPV 疫苗

第 6 章人乳頭瘤病毒 (HPV) 疫苗市場分析：按適應症分類

• 簡介
• 宮頸癌
• 肛門癌
• 陰道癌
• 外陰癌
• 生殖系統癌症
• 其他

第 7 章按性別分列的人乳頭瘤病毒 (HPV) 疫苗市場分析

• 簡介
• 男
• 女

第 8 章人乳頭瘤病毒 (HPV) 疫苗市場分析：按地區

• 簡介
• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 德國
  • 法國
  • 英國
  • 意大利
  • 其他
• 中東和非洲
  • 沙特阿拉伯
  • 阿拉伯聯合酋長國
  • 以色列
  • 其他
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 台灣
  • 泰國
  • 印度尼西亞
  • 其他

第 9 章衝突信息

• 主要公司和戰略分析
• 新興公司和市場盈利能力
• 合併、收購、協議和合作
• 供應商競爭力矩陣

第十章公司簡介

• Merck & Co., Inc.
• GSK plc
• INOVIO Pharmaceuticals

The human papilloma virus (HPV) market is projected to grow at a CAGR of 14.68% during the forecasted period to reach a market size of US$5,296.808 million by 2027, from US$2,030.136 million in 2020.

Along with other immunizations, routine vaccination is advised for all nations according to WHO guidelines. The Human Papilloma Virus (HPV) vaccine offers defense against specific strains of the virus that can cause genital warts or cancer. Along with other immunizations, routine vaccination is advised for all nations according to WHO guidelines. These vaccinations are regarded as safe and effective medications and are included on the "World Health Organization's list of Essential Medicines." The global market for the Human Papilloma Virus (HPV) vaccine is being boosted by the rise in cervical cancer cases. Increased government measures will increase public awareness of HPV and cervical cancer, which will help the market for HPV vaccines. However, a stringent regulatory licensing procedure for the vaccines may limit market expansion.

Effectiveness of HPV Vaccines to Boost Sales

The effectiveness and protection offered by HPV vaccines to lessen the negative effects associated with such infections are one of the most important and significant market drivers. Clinical trials have demonstrated the effectiveness and safety of both bivalent and polyvalent vaccinations in preventing HPV infections and cancer. Additionally, it is projected that the rising incidence of cervical cancer in various nations would boost sales of the human papillomavirus vaccine, resulting in a stellar market expansion. The market is also being driven by an increase in HPV vaccination production capacity to keep global supply and demand in balance.

By Geography

Geographically, the Human Papilloma Virus Vaccine Market is segmented as North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America holds major share of the market whereas Asia-Pacific is anticipated to have a faster-growing market.

Key Developments:

• June 2020: The FDA has authorized an additional indication for GARDASIL9 for the prevention of oropharyngeal and other head and neck cancers brought on by HPV Types 16, 18, 31, 33, 45, 52, and 58, according to a statement from Merck, often known as MSD. Based on its effectiveness in preventing HPV-related anogenital disease, the accelerated approval process has authorized the indication for oropharyngeal and head and neck cancer. The confirmation and description of clinical benefit in a confirmatory trial may be necessary in order for this indication to continue receiving approval. A vaccination called GARDASIL 9 is recommended for females between the ages of 9 and 45 for the prevention of genital warts, cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck malignancies brought on by the Human Papillomavirus (HPV). For the prevention of genital warts brought on by HPV and precancerous or dysplastic lesions as well as other head and neck cancers in males up to the age of 45, GARDASIL 9 is recommended.
• Dec 2021: Updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL) have been made by INOVIO, a biotechnology firm focused on bringing precisely tailored DNA medicines to market to help protect people from infectious diseases and cure cancer and HPV-associated disorders. These updates include a one-year follow-up of efficacy and safety data in participants from REVEAL1, the completion of REVEAL2 enrolment, and In addition, ApolloBio Corp. , INOVIO's research partner in Greater China (mainland China, Hong Kong, Macao, Taiwan), dosed the first subject in a separate Phase 3 trial in China.

Product Offerings:

• GARDASIL 9 vaccine: GARDASIL 9 vaccine by Merck is a vaccination that is recommended for females between the ages of 9 and 45 for Human Papillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 causing cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers and Types 6, 11, and 6 and 11 of the HPV are also responsible for genital warts. GARDASIL 9 is recommended for use in males between the ages of 9 and 45 in order to prevent genital warts brought on by HPV Types 6 and 11, as well as anal, oropharyngeal, and other head and neck malignancies brought on by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Based on its effectiveness in preventing HPV-related anogenital disease, the accelerated approval process has authorized the indication for oropharyngeal and head and neck cancer.
• Cervarix vaccine: The GlaxoSmithKline-produced vaccine Cervarix is recommended for use starting at age 9 in order to prevent premalignant anogenital lesions (cervical, vulvar, vaginal, and anal cancers), as well as cervical and anal cancers that are connected to specific oncogenic Human Papillomavirus (HPV) types ( HPV 16 and 18). Cervarix is used for deltoid intramuscular injection. It has been demonstrated that the Cervarix vaccine shields women from a significant portion of the precursor lesions of cervical cancer brought on by these two HPV strains.

Market Segmentation:

• By Type

Quadrivalent HPV Vaccine

Bivalent HPV Vaccine

9-Valent HPV Vaccine

• By Indication

Cervical Cancer

Anal Cancer

Vaginal Cancer

Vulvar Cancer

Mouth Cancer

Genital Warts

• By Gender

Male

Female

• By Geography

North America

• USA
• Mexico
• Canada

South America

• Brazil
• Argentina
• Others

Europe

• Germany
• France
• United Kingdom
• Italy
• Others

Middle East and Africa

• Saudi Arabia
• UAE
• Israel
• Others

Asia Pacific

• India
• China
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. COVID-19 Scenario
• 1.3. Market Definition
• 1.4. Market Segmentation

2. RESEARCH METHODOLOGY

• 2.1. Research Data
• 2.2. Assumptions

3. EXECUTIVE SUMMARY

• 3.1. Research Highlights

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. HUMAN PAPILLOMA VIRUS VACCINE MARKET ANALYSIS, BY TYPE

• 5.1. Introduction
• 5.2. Quadrivalent HPV Vaccine
• 5.3. Bivalent HPV vaccine
• 5.4. 9-Valent HPV Vaccine

6. HUMAN PAPILLOMA VIRUS VACCINE MARKET ANALYSIS, BY INDICATION

• 6.1. Introduction
• 6.2. Cervical Cancer
• 6.3. Anal Cancer
• 6.4. Vaginal Cancer
• 6.5. Vulvar Cancer
• 6.6. Genital Cancer
• 6.7. Others

7. HUMAN PAPILLOMA VIRUS VACCINE MARKET ANALYSIS, BY GENDER

• 7.1. Introduction
• 7.2. Male
• 7.3. Female

8. HUMAN PAPILLOMA VIRUS VACCINE MARKET ANALYSIS, BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Italy
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. Japan
  • 8.6.3. India
  • 8.6.4. South Korea
  • 8.6.5. Taiwan
  • 8.6.6. Thailand
  • 8.6.7. Indonesia
  • 8.6.8. Others

9. COMPETITIVE INTELLIGENCE

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

• 10.1. Merck & Co., Inc.
• 10.2. GSK plc
• 10.3. INOVIO Pharmaceuticals

List is not exhaustive